Interim analysis of the Daliah trial - a randomized controlled phase iii clinical trial Comparing recombinant interferon alpha-2 vs. Hydroxyurea in MPN patients.

Trine Alma Knudsen, Dennis Lund Hansen, Lukas Frans Ocias, Ole Weiss Bjerrum, Daniel El Fassi, Mikael Frederiksen, Lasse Kjær, Thomas Kielsgaard Kristensen, Torben Kruse, Hans Torben Mourits-Andersen, Peter Møller, Ulrik Malthe Overgaard, Marianne Tang Severinsen, Vibe Henriette Skov, Jesper Stentoft, Jørn Starklint, Karin de Stricker, Mads Thomassen, Thomas Stauffer Larsen, Hans Carl Hasselbalch

Research output: Contribution to conference without publisher/journalConference abstract for conferenceResearchpeer-review

Original languageEnglish
Publication date15. Jun 2018
Publication statusPublished - 15. Jun 2018
EventEuropean Hematology Association 23rd congress EHA 2018 - Stockholm , Sweden
Duration: 14. Jun 201817. Jun 2018

Conference

ConferenceEuropean Hematology Association 23rd congress EHA 2018
CountrySweden
CityStockholm
Period14/06/201817/06/2018

Cite this

Knudsen, T. A., Lund Hansen, D., Ocias, L. F., Weiss Bjerrum, O., El Fassi, D., Frederiksen, M., Kjær, L., Kielsgaard Kristensen, T., Kruse, T., Mourits-Andersen, H. T., Møller, P., Overgaard, U. M., Severinsen, M. T., Skov, V. H., Stentoft, J., Starklint, J., de Stricker, K., Thomassen, M., Larsen, T. S., & Hasselbalch, H. C. (2018). Interim analysis of the Daliah trial - a randomized controlled phase iii clinical trial Comparing recombinant interferon alpha-2 vs. Hydroxyurea in MPN patients.. Abstract from European Hematology Association 23rd congress EHA 2018, Stockholm , Sweden.